Arrowhead Pharmaceuticals Statistics Share Statistics Arrowhead Pharmaceuticals has 138.26M
shares outstanding. The number of shares has increased by 11.09%
in one year.
Shares Outstanding 138.26M Shares Change (YoY) 11.09% Shares Change (QoQ) 0.57% Owned by Institutions (%) 76.86% Shares Floating 128.31M Failed to Deliver (FTD) Shares 18 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 12.98M, so 9.39% of the outstanding
shares have been sold short.
Short Interest 12.98M Short % of Shares Out 9.39% Short % of Float 12.12% Short Ratio (days to cover) 5.19
Valuation Ratios The PE ratio is -3.87 and the forward
PE ratio is -8.27.
Arrowhead Pharmaceuticals's PEG ratio is
-0.02.
PE Ratio -3.87 Forward PE -8.27 PS Ratio 653.4 Forward PS 11.9 PB Ratio 12.51 P/FCF Ratio -3.84 PEG Ratio -0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Arrowhead Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.74,
with a Debt / Equity ratio of 2.75.
Current Ratio 6.74 Quick Ratio 6.74 Debt / Equity 2.75 Debt / EBITDA -0.91 Debt / FCF -0.84 Interest Coverage -18.58
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $5.83K Profits Per Employee $-984.39K Employee Count 609 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -2.77M Effective Tax Rate 0.45%
Stock Price Statistics The stock price has increased by 20.43% in the
last 52 weeks. The beta is 0.95, so Arrowhead Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.95 52-Week Price Change 20.43% 50-Day Moving Average 18.37 200-Day Moving Average 17.58 Relative Strength Index (RSI) 82.33 Average Volume (20 Days) 2,146,540
Income Statement In the last 12 months, Arrowhead Pharmaceuticals had revenue of 3.55M
and earned -599.49M
in profits. Earnings per share was -5.
Revenue 3.55M Gross Profit 3.55M Operating Income -601.08M Net Income -599.49M EBITDA -561.51M EBIT -580.11M Earnings Per Share (EPS) -5
Full Income Statement Balance Sheet The company has 102.69M in cash and 510.55M in
debt, giving a net cash position of -407.87M.
Cash & Cash Equivalents 102.69M Total Debt 510.55M Net Cash -407.87M Retained Earnings -1.63B Total Assets 1.38B Working Capital 752.39M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -462.85M
and capital expenditures -141.47M, giving a free cash flow of -604.32M.
Operating Cash Flow -462.85M Capital Expenditures -141.47M Free Cash Flow -604.32M FCF Per Share -5.05
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -16927.06% and -16882.37%.
Gross Margin 100% Operating Margin -16927.06% Pretax Margin -17247.54% Profit Margin -16882.37% EBITDA Margin -15812.81% EBIT Margin -16927.06% FCF Margin -17018.3%
Dividends & Yields ARWR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ARWR is $38,
which is 35.7% higher than the current price. The consensus rating is "Buy".
Price Target $38 Price Target Difference 35.7% Analyst Consensus Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 17, 2011. It was a
backward
split with a ratio of 1:10.
Last Split Date Nov 17, 2011 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 1.98 Piotroski F-Score 6
